Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yolanda Piña

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Investigative Ophthalmology & Visual Science|August 13, 2010
Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastomaYolanda Piña, Samuel K Houston, Timothy G Murray, et al.
Journal of Neurology|November 22, 2019
Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytomaYolanda Piña, Michael J Fusco, Robert J Macaulay, et al.
Frontiers in Oncology|December 8, 2025
Successful response in advanced leptomeningeal disease from pleomorphic xanthoastrocytoma with BRAF/MEK inhibitors: a case reportMaria A Jacome, Robert J Macaulay, Edwin Peguero, et al.
Ophthalmic Research|March 27, 2009
Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculatureYolanda Piña, Colleen M Cebulla, Timothy G Murray, et al.
Oncotargets and Therapy|September 13, 2022
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple MyelomaSyeda Saba Kareem, Neena Viswanathan, Solmaz Sahebjam, et al.
Investigative Ophthalmology & Visual Science|January 24, 2012
Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumorsYolanda Piña, Christina Decatur, Timothy G Murray, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 16, 2012
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumorsYolanda Piña, Samuel K Houston, Timothy G Murray, et al.
Plos One|November 10, 2010
Antiangiogenic activity of 2-deoxy-D-glucoseJaime R Merchan, Krisztina Kovács, Jaclyn W Railsback, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 23, 2011
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumorsSamuel K Houston, Yolanda Piña, Timothy G Murray, et al.
Investigative Ophthalmology & Visual Science|July 11, 2008
Basic fibroblast growth factor impact on retinoblastoma progression and survivalColleen M Cebulla, Maria-Elena Jockovich, Yolanda Piña, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Investigative Ophthalmology & Visual Science|August 13, 2010
Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastomaYolanda Piña, Samuel K Houston, Timothy G Murray, et al.
Journal of Neurology|November 22, 2019
Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytomaYolanda Piña, Michael J Fusco, Robert J Macaulay, et al.
Frontiers in Oncology|December 8, 2025
Successful response in advanced leptomeningeal disease from pleomorphic xanthoastrocytoma with BRAF/MEK inhibitors: a case reportMaria A Jacome, Robert J Macaulay, Edwin Peguero, et al.
Ophthalmic Research|March 27, 2009
Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculatureYolanda Piña, Colleen M Cebulla, Timothy G Murray, et al.
Oncotargets and Therapy|September 13, 2022
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple MyelomaSyeda Saba Kareem, Neena Viswanathan, Solmaz Sahebjam, et al.
Investigative Ophthalmology & Visual Science|January 24, 2012
Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumorsYolanda Piña, Christina Decatur, Timothy G Murray, et al.
Clinical Ophthalmology (Auckland, N.Z.)|June 16, 2012
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumorsYolanda Piña, Samuel K Houston, Timothy G Murray, et al.
Plos One|November 10, 2010
Antiangiogenic activity of 2-deoxy-D-glucoseJaime R Merchan, Krisztina Kovács, Jaclyn W Railsback, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 23, 2011
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumorsSamuel K Houston, Yolanda Piña, Timothy G Murray, et al.
Investigative Ophthalmology & Visual Science|July 11, 2008
Basic fibroblast growth factor impact on retinoblastoma progression and survivalColleen M Cebulla, Maria-Elena Jockovich, Yolanda Piña, et al.
Pageof 4